The estimated Net Worth of Stephen Rosenfield is at least $1.18 Million dollars as of 24 August 2018. Mr. Rosenfield owns over 1,362,250 units of Geron stock worth over $164,625 and over the last 13 years he sold GERN stock worth over $0. In addition, he makes $1,014,860 as Executive Vice President, Corporate Secretary, and Chief Legal Officer at Geron.
Stephen has made over 1 trades of the Geron stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,362,250 units of GERN stock worth $2,574,653 on 24 August 2018.
The largest trade he's ever made was exercising 1,362,250 units of Geron stock on 24 August 2018 worth over $2,574,653. On average, Stephen trades about 90,817 units every 0 days since 2012. As of 24 August 2018 he still owns at least 37,500 units of Geron stock.
You can see the complete history of Mr. Rosenfield stock trades at the bottom of the page.
Stephen N. Rosenfield J.D. serves as Executive Vice President, Corporate Secretary, Chief Legal Officer of the Company. Previously, he served as our Executive Vice President, General Counsel and Corporate Secretary from February 2012 to January 2019, General Counsel and Secretary since January 2012 and Secretary since October 2011. From July 2009 to February 2012, Mr. Rosenfield served as a consultant to private companies. From June 2004 until June 2009, Mr. Rosenfield held several positions at Tercica, Inc., an endocrinology-oriented biopharmaceutical company, and through its acquisition by Ipsen, S.A. in October 2008, including General Counsel and Secretary. Prior to joining Tercica, Mr. Rosenfield served as the Executive Vice President of Legal Affairs, General Counsel and Secretary of InterMune, Inc., a biotechnology company that focused on pulmonology and fibrotic diseases. Prior to joining InterMune, Mr. Rosenfield was an attorney at Cooley LLP, an international law firm, where he served as outside counsel for biotechnology and technology clients. Mr. Rosenfield received a B.S. from Hofstra University and a J.D. from Northeastern University School of Law.
As the Executive Vice President, Corporate Secretary, and Chief Legal Officer of Geron, the total compensation of Stephen Rosenfield at Geron is $1,014,860. There are 3 executives at Geron getting paid more, with John Scarlett having the highest compensation of $1,941,140.
Stephen Rosenfield is 70, he's been the Executive Vice President, Corporate Secretary, and Chief Legal Officer of Geron since 2019. There are 1 older and 16 younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..
Stephen's mailing address filed with the SEC is C/O GERON CORPORATION, 919 E. HILLSDALE BLVD, SUITE 250, FOSTER CITY, CA, 94404.
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury, and Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: